Skip to content

Clinical heterogeneity of advanced prostate cancer based on PCT-SWATH/DIA proteomics

Clinical heterogeneity of prostate cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100054836
Enrollment
Unknown
Registered
2021-12-28
Start date
2022-03-01
Completion date
Unknown
Last updated
2022-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Case series:No

Sponsors

The Second Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Agree to participate in this research and sign the informed consent; 2. Aged 18-85 years, gender male; 3. Histopathologically diagnosed prostate cancer; 4. Imaging (CT/bone scan) found metastases (according to RECIST criteria); 5. Receive systemic ADT treatment after pathological diagnosis and progress to CRPC.

Exclusion criteria

Exclusion criteria: 1. The patient's pathological tissue test type is neuroendocrine/small cell prostate cancer; 2. Suffering from other tumors; 3. The case received radiotherapy or chemotherapy before and after the diagnosis; 4. Have a history of infection with human immunodeficiency virus, or have other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation, or have a history of organ transplantation.

Design outcomes

Primary

MeasureTime frame
Proteome;

Countries

China

Contacts

Public ContactLiu Zhiyu

The Second Affiliated Hospital of Dalian Medical University

18842643812@163.com+86 17709870009

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026